Fmr LLC Cassava Sciences Inc Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Fmr LLC holds 1,359 shares of SAVA stock, worth $41,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,359

Previous 11,788 88.47%

Holding current value

$41,204

Previous $239,000 93.31%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$12.35 - $26.11 $128,798 - $272,301	-10,429 Reduced 88.47%	1,359 $16,000
Q1 2024 May 13, 2024	BUY	$18.44 - $26.41 $179,826 - $257,550	9,752 Added 478.98%	11,788 $239,000
Q4 2023 Feb 13, 2024	SELL	$12.64 - $30.11 $37,743 - $89,908	-2,986 Reduced 59.46%	2,036 $45,000
Q3 2023 Nov 13, 2023	BUY	$16.64 - $25.32 $47,923 - $72,921	2,880 Added 134.45%	5,022 $83,000
Q2 2023 Aug 11, 2023	BUY	$21.59 - $27.88 $10,233 - $13,215	474 Added 28.42%	2,142 $52,000
Q1 2023 May 11, 2023	SELL	$23.46 - $36.44 $69,957 - $108,664	-2,982 Reduced 64.13%	1,668 $40,000
Q4 2022 Feb 13, 2023	SELL	$27.82 - $44.16 $8,485 - $13,468	-305 Reduced 6.16%	4,650 $137,000
Q3 2022 Nov 10, 2022	BUY	$16.33 - $51.06 $71,607 - $223,898	4,385 Added 769.3%	4,955 $207,000
Q2 2022 Aug 12, 2022	SELL	$17.22 - $38.47 $688 - $1,538	-40 Reduced 6.56%	570 $16,000
Q1 2022 May 13, 2022	BUY	$32.6 - $53.05 $19,886 - $32,360	610 New	610 $23,000
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $208 - $676	-5 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$32.15 - $89.72 $160 - $448	5 New	5 $0

Others Institutions Holding SAVA

# of Institutions

184

Shares Held

13.3M

Call Options Held

1.38M

Put Options Held

2.04M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.22B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account